LOS ANGELES--(BUSINESS WIRE)--The Gores Group announced today it has completed the sale of Therakos to Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading specialty biopharmaceutical company, in a transaction valued at $1.325 billion. Therakos is the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis...
More...
